Australian life sciences company, QBiotics Group Limited, has signed an agreement with French-headquartered Virbac, one of the largest dedicated animal health companies globally, to market and distribute its canine anticancer drug, tigilanol tiglate. Under the agreement, Virbac is granted the right to market and distribute QBiotics’ anticancer pharmaceutical to veterinary markets in the USA, Switzerland, Norway, UK and EU, with potential of future expansion to Australia, New Zealand and Canada.
Thomson Geer Partner, Roberta Bozzoli, advised QBiotics in relation to this agreement.
Worldwide, as many as 1 in 4 dogs will develop cancer at some time in their lives, and almost 50% of dogs over the age of 10 will die of the disease. To date there are only a very small number of treatment options for cancer in animals, providing a significant opportunity for new treatments in this growing market. QBiotics’ tigilanol tiglate has demonstrated anticancer potential in a range of solid tumours in dogs during clinical trials.
QBiotics’ commercial strategy is to launch tigilanol tiglate into veterinary markets to provide cash flow for further development of QBiotics’ technology in human cancers and wound healing.